Loading…
Loading…
Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
Stock futures are mixed to start the shortened week as oil prices rise
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Boston Scientific said on Tuesday a cybersecurity incident that disrupted manufacturing and order shipments globally is likely to have a material impact on its third-quarter and full-year 2026 results.
AlphaGrep UK Ltd acquired a new position in shares of Boston Scientific Corporation (NYSE: BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,906 shares of the medical equipment provider's stock, valued at approximately $978,000. Other large investors
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.